semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure, Congestive Cardiovascular Diseases Heart Diseases (PCP) 1. Provider must be the health professional who is managing the potential patient enrollee's heart failure medication(s) (Patients) Participant has been diagnosed with Heart Failure (HF) Self reported family income is less than $30,000/year Has experienced at least one hospitalization for acute, decompensated, HF within the previous 6 months based upon Being admitted for symptoms of HF (ex: peripheral edema, shortness of breath and fatigue), and responding to anti-failure therapy such as diuretics and other anti-failure therapy such as ACE Inhibitors, ARBs, or Beta blockers Has evidence of systolic dysfunction, defined by an ejection <50 by 1 of 3 methods: echocardiography, radiographic contrast ventriculography, or nuclear ventriculography; done within the last year Age ≥ 18 years Currently resides in Cook County, Illinois  (PCP) Health providers will be excluded from enrollment if they are Still in their residency or training period A member of the CHART research staff (Patients) Patients will be excluded from enrollment if they have An uncertain 12-month prognosis Listed for imminent cardiac transplant Has an advanced directive of "Do not resuscitate" Has uncertain 12-Month Prognosis, as adjudicated by the Principal Investigator
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Constipation Age 18-80 constipation defined by the Rome II  Past history of abdominal surgery past history of diabetes mellitus past history of hypothyroidism past history of inflammatory bowel disease past history of significant psychiatric disturbances past history of drug abuse past history of cardiac pacemakers past history of metal implants patients who cannot travel to keep the follow up patients who are prisoners
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Heart Failure Men and women ≥ 60 years Admission to hospital for worsening HF  History of uncontrolled hypertension Severe valve disease End-stage (Stage D) HF, including treatment with chronic ionotropic drugs or left ventricular assist device support Advanced malignancy or other medical condition with life expectancy less than 2 years or undergoing active chemotherapy or radiation therapy Advanced chronic kidney disease (CKD) defined as estimated glomerular filtration rate (GFR) < 20 mL/min/1.73 m2 based upon the Modification of Diet in Renal Disease (MDRD) study equation), or on chronic or intermittent dialysis or dialysis anticipated within the next 6 months Chronic anemia with hemoglobin < 9 gm/dl for males, < 8 gm/dl for females or acute anemia requiring transfusion of 2 or more units of blood
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Heart Failure Left Ventricular Dysfunction > 18 years of age Hospital admission for acute heart failure as defined by the presence of acute dyspnea and the presence of clinical signs of heart failure on physical examination Where available, NT-proBNP >900 pg/ml, >1800 pg/ml if the patient has atrial fibrillation at screening or >450 pg/ml if BMI > 35 kg/m2, LVEF <45% assessed by echocardiography or other method within the previous 12 months Background therapy with at least ACE-inhibitor or angiotensin receptor blocker (ARB) and beta-blocker (unless beta-blocker is contraindicated due to severe volume overload, low output heart failure, or cardiogenic shock) Available for regular follow up  Currently being treated with Hydralazine and/or nitrates or a history of intolerance to oral therapy with either hydralazine or nitrates . Any intravenous treatment for heart failure, except IV furosemide (eg. IV inotropes, pressors, nitrates or nesiritide) at the time of screening Systolic blood pressure <100 mmHg Plan for revascularization Greater than 96 hours after admission Reversible etiology of acute heart failure such as myocarditis, acute myocardial infarction, arrhythmia. Acute MI is defined as symptoms and major electrocardiogram (ECG) changes(i.e., ST segment elevations), and arrhythmia includes unstable heart rates above 120/min or below 50/min Hypertrophic obstructive cardiomyopathy, constrictive cardiomyopathy, endomyocardial fibroelastosis Known severe congenital heart disease (such as uncorrected tetralogy of fallot or transposition of the aorta) Severe aortic or mitral stenosis or severe rheumatic mitral regurgitation Renal impairment (defined by creatinine >3 mg/dL) at screening or on any type of dialysis
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Obstructive Sleep Apnea Pre-menopausal females aged ≥ 18 years Current positive airway pressure (PAP)(CPAP or APAP) therapy user with 'current' defined as on PAP therapy for at least 1 month prior to study entry Diagnostic PSG available Diagnosis of mild-moderate OSA (AHI ≤ 30) Participants willing and able to give written informed consent  Participants currently using Bi-level PAP Participants currently using supplemental oxygen Participants who are pregnant Subjects who have a pre existing lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (< 2years) case of pneumonia or lung infection; lung injury) Participants who the researcher believes are unsuitable for because either they do not comprehend English they are unable to provide written informed consent they are physically unable to comply with the protocol
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-95.0,  Heart Rate Control in ICD Patients With Heart Failure Age ≥ 18 years Patients with stable chronic heart failure implanted with mono-cameral or bicameral ICD with a home monitoring remote control Moderate to severe left ventricular dysfunction (FE ≤ 40%) Any cause of heart failure was allowed apart congenital heart disease Bicameral ICD programmed in DDD or AAI/DDD with AV interval < 300 msec Rest ECG heart rate ≥70 bpm Sinus rhythm In therapy with low-dose of beta-blocker (bisoprolol 1,25-2,5 mg) and with the maximum dose tolerated of angiotensin-converting enzyme inhibitor or blockade of angiotensin II receptor, mineralocorticoid antagonist, antiplatelet and lipid-lowering therapy, unless contraindicated  Inability of providing informed consent Age < 18 years State of pregnancy or lactation Recent (<2 months) myocardial infarction Contraindications to beta-blockers and ivabradine Rest ECG heart rate < 70 bpm No sinus rhythm Administration of non-dihydropyridinic calcium channels antagonists, digitalis, class I antiarrhythmic drugs, strong inhibitors of cytochrome P450 3A4 at the time of enrollment
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metabolic Syndrome Coronary Heart Disease Chronic Heart Failure Elderly healthy subjects : with no MetS and no-documented CHD, both males and females, aged>60 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living Patients with metabolic syndrome and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. MetS will be defined according to recent updated presence of at least three of five namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy) Patients with documented stable chronic heart failure will be recruited if they show the following ≥18 years Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by MUGA Scan, echo or radiological ventriculography) NYHA functional class I-III Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation) Able to perform an symptom limited exercise test Capacity and willingness to sign the informed consent form  For healthy elderly subjects age under 60 years lack of expressed written consent metabolic syndrome coronary heart disease chronic systolic heart failure resting left ventricular ejection fraction < 40 % symptomatic aortic stenosis chronic atrial fibrillation malignant exertional arrhythmias
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 21.0-130.0,  Heart Failure All 6 need to be met for enrollment of the patient in the study Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below dyspnea or respiratory distress or tachypnea at rest or with minimal exertion evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met) pulmonary congestion/edema at physical exam OR chest X-Ray plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction <50%) at most recent assessment by any imaging modality (within 12 months) The patient is now clinically stable and meets standard for hospital discharge as documented by all the 3 conditions listed below absence of dyspnea or pulmonary congestion/distress at rest  Subjects will not be eligible if they meet any of the following 15 The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy or brady-arrhythmias Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries Previous or planned implantation of left ventricular assist devices or heart-transplant Chronic use of intravenous inotropes Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]) Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Decompensated Heart Failure Heart Failure Patients ≥ 18 years of age and English-speaking who are admitted to the General Cardiology or Heart Failure Services at the University of North Carolina Hospitals with acute decompensated heart failure (ADHF) Patients deemed by the health care team to require hemodynamic monitoring with a pulmonary artery catheter and inotropic therapy. Patients receiving at least 3 doses of continued beta blocker therapy with carvedilol, metoprolol succinate, or metoprolol tartrate and patients receiving no beta blocker therapy or have missed at least 5 doses of beta-blocker therapy  Concomitant treatment with other beta blockers, non-selective alpha blockers (e.g. terazosin, prazosin, doxazosin), non-dihydropyridine calcium antagonists, antiarrhythmic agents except for chronic stables doses of amiodarone, dofetilide or mexiletine Use of inotropes or IV vasoactive agents within 7 days or at time of enrollment Patients with hemodynamically unstable arrhythmias (e.g., Systolic Blood Pressure (SBP) < 80, Heart Rate (HR) > 110), uncorrected primary valvular disease, or current mechanical support including left ventricular assist device (LVADs), Impella devices and balloon pumps Patients who have missed more than 1 dose of beta blocker within 72 hours of starting inotrope No subjects will be excluded based upon race, gender or ethnicity
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 7.0-999.0,  Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) Subjects age 7 or older; cohort 1A must be adult and wheelchair-dependent Proven alpha-sarcoglycan deficiency by muscle biopsy or DNA testing Onset of weakness by 5 years age based on history of difficulty running, jumping and climbing stairs Subject enrolled in Cohort 1A must be adult and wheelchair dependent Subjects enrolled in Cohorts 1B or 2 must be able to walk independently, but must exhibit signs of lower extremity weakness (i.e. a Gowers' sign, use a handrail for climbing stairs) and walk ≤ 80% of predicted distance on the 6MWT based on normative data Males and females of any ethnic group will be eligible Ability to cooperate with muscle testing Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate), during the first six months after gene therapy (females) or until two negative sperm samples are obtained post gene transfer (males)  Active viral infection based on clinical observations The presence of SGCA mutations without weakness or loss of function Symptoms or signs of cardiomyopathy, including Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs Echocardiogram with ejection fraction below 40% Serological evidence of HIV infection, or Hepatitis A, B or C infection Diagnosis of (or ongoing treatment for) an autoimmune disease Abnormal laboratory values considered clinically significant (GGT > 3XULN, bilirubin ≥ 3.0 mg/dL , creatinine ≥ 1.8 mg/dL, Hgb < 8 or > 18 g/Dl; WBC > 15,000 per cmm) Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer Pregnancy
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Congestive Heart Failure Congestive heart failure patients between tne ages 40 to 90,all stages of the disease  non
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Obstructive Sleep Apnoea (OSA) Confirmed OSA (at the time of original diagnosis) with an oxygen desaturation index (ODI) of >20/h Currently >20/h oxygen desaturations (≥4% dips) during an ambulatory nocturnal pulse oximetry performed on the last night of a 4-night period without CPAP Treated with CPAP for more than 12 months, minimum compliance 4h/night, apnoea-hypopnoea index (AHI) <10 with treatment (according to CPAP download) and current ESS <10 Age between 20 and 75 years at trial entry  Previous ventilatory failure (awake SpO2 <93% and PaCO2>6kPa) Unstable, untreated coronary or peripheral artery disease, severe arterial hypertension or hypotension (>180/110 or <90/60mmHg) Previously diagnosed with Cheyne-Stokes breathing Current professional driver; any previous sleep related accident Acute inflammatory disease Acute or chronic hepatic disease Renal failure or renal replacement therapy Use of inhaled drugs
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Congestive Heart Failure CHF Subjects: 21 years of age or greater, with clinically confirmed CHF or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure Subjects with Potentially confounding comorbidities: Non-CHF subjects 21 years of age or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD) Healthy Subjects: apparently healthy subjects greater than 45 years of age, with no prior history of cardiac-related disease  Apparently healthy subjects with a history of MI, CHF or other cardiac-related disease Subjects with acute decompensated heart failure currently on nesiritide therapy Subjects having participated in another experimental drug, biologic, or invasive device study within 30 days prior to signing informed consent for this study, or enrolled concurrently in any other investigative study; and Subjects unable to or refusing to provide written informed consent
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Male or female patients aged >=18 years Uncontrolled asthma on medium doses of ICS+LABA with ACQ >=1.5 Pre-bronchodilator FEV1 ≥40% and <80% of their predicted normal value  Pregnant or lactating women Diagnosis of COPD Patients treated for asthma exacerbations in the 4 weeks prior to study entry Patients who are in therapy for gastroesophageal reflux disease Patients who have a clinically significant cardiovascular condition
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 75.0-999.0,  Heart Failure years or older diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure' diagnosis had to be confirmed by a recent echocardiogram  not Dutch speaking treatment restrictions had been applied on admission